STARD13-correlated CeRNA Network-directed Inhibition on YAP/TAZ Activity Suppresses Stemness of Breast Cancer Via Co-regulating Hippo and Rho-GTPase/F-actin Signaling

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2018 Jun 1

PMID 29848346

Citations 63

Authors

Lufeng Zheng

Chenxi Xiang

Xiaoman Li

Qianqian Guo

Lanlan Gao

Haiwei Ni

Yufeng Xia

Tao Xi

Affiliations

Soon will be listed here.

Abstract

Background: Targeting cancer stem cells is critical for suppressing cancer progression and recurrence. Finding novel markers or related pathways could help eradicate or diagnose cancer in clinic.

Methods: By constructing STARD13-correlated ceRNA 3'UTR stable overexpression or knockdown breast cancer cells, we aimed to explore the effects of STARD13-correlated ceRNA network on breast cancer stemness in vitro and in vivo. Further RNA-sequencing was used to analyze transcriptome change in combination with functional studies on candidate signaling. Clinical samples obtained from The Cancer Genome Atlas data were used to validate the correlation between STARD13 and related pathways. Finally, in vitro and in vivo experiments were used to examine the effects of STARD13-correlated ceRNA network on chemotherapy sensitivity/resistance.

Results: Here, we revealed that this ceRNA network inhibited stemness of breast cancer. Mechanistically, we found that activation of STARD13-correlated ceRNA network was negatively correlated with YAP/TAZ activity in breast cancer. Specifically, this ceRNA network attenuated YAP/TAZ nuclear accumulation and transcriptional activity via collectively modulating Hippo and Rho-GTPase/F-actin signaling. Finally, we demonstrated that YAP/TAZ transcriptional activity regulated by this ceRNA network was involved in chemoresistance.

Conclusions: Our results uncover a novel mechanism of YAP/TAZ activation in breast cancer and propose the possibility to drive STARD13-correlated ceRNA network to inhibit breast cancer stem cell traits.

Citing Articles

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality.

Guo Q, Qin H, Chen Z, Zhang W, Zheng L, Qin T Genes Dis. 2025; 12(3):101311.

PMID: 40034124 PMC: 11875185. DOI: 10.1016/j.gendis.2024.101311.

Engrailed 2 facilitates progression of triple-negative and HER2-enriched breast cancer by binding to enhancer region of Tenascin-C.

Chen D, Yin R Discov Oncol. 2024; 15(1):705.

PMID: 39581954 PMC: 11586318. DOI: 10.1007/s12672-024-01471-6.

RhoA-ROCK2 signaling possesses complex pathophysiological functions in cancer progression and shows promising therapeutic potential.

Ning Y, Zheng M, Zhang Y, Jiao Y, Wang J, Zhang S Cancer Cell Int. 2024; 24(1):339.

PMID: 39402585 PMC: 11475559. DOI: 10.1186/s12935-024-03519-7.

Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC).

Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A Cancers (Basel). 2024; 16(17).

PMID: 39272915 PMC: 11394539. DOI: 10.3390/cancers16173057.

Competing endogenous RNAs regulatory crosstalk networks: The messages from the RNA world to signaling pathways directing cancer stem cell development.

Aria H, Azizi M, Nazem S, Mansoori B, Darbeheshti F, Niazmand A Heliyon. 2024; 10(15):e35208.

PMID: 39170516 PMC: 11337742. DOI: 10.1016/j.heliyon.2024.e35208.

References

Li C, Zheng L, Xin Y, Tan Z, Zhang Y, Meng X . The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer. FEBS Lett. 2017; 591(7):991-1000. DOI: 10.1002/1873-3468.12608. View

Denzler R, McGeary S, Title A, Agarwal V, Bartel D, Stoffel M . Impact of MicroRNA Levels, Target-Site Complementarity, and Cooperativity on Competing Endogenous RNA-Regulated Gene Expression. Mol Cell. 2016; 64(3):565-579. PMC: 5101187. DOI: 10.1016/j.molcel.2016.09.027. View

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

Nagaraja G, Kandpal R . Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochem Biophys Res Commun. 2003; 313(3):654-65. DOI: 10.1016/j.bbrc.2003.12.001. View

Cidado J, Wong H, Rosen D, Cimino-Mathews A, Garay J, Fessler A . Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016; 7(5):6281-93. PMC: 4868756. DOI: 10.18632/oncotarget.7057. View

Pascual-Vargas P, Cooper S, Sero J, Bousgouni V, Arias-Garcia M, Bakal C . RNAi screens for Rho GTPase regulators of cell shape and YAP/TAZ localisation in triple negative breast cancer. Sci Data. 2017; 4:170018. PMC: 5332010. DOI: 10.1038/sdata.2017.18. View

Lu M, Tang B, Zeng S, Hu C, Xie R, Wu Y . Long noncoding RNA BC032469, a novel competing endogenous RNA, upregulates hTERT expression by sponging miR-1207-5p and promotes proliferation in gastric cancer. Oncogene. 2015; 35(27):3524-34. DOI: 10.1038/onc.2015.413. View

Tang F, Zhang R, He Y, Zou M, Guo L, Xi T . MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 2012; 7(5):e35435. PMC: 3365056. DOI: 10.1371/journal.pone.0035435. View

10.

Cheng D, Xiang Y, Ji L, Lu X . Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. Tumour Biol. 2015; 36(2):479-88. DOI: 10.1007/s13277-015-3093-z. View

11.

Ala U, Karreth F, Bosia C, Pagnani A, Taulli R, Leopold V . Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proc Natl Acad Sci U S A. 2013; 110(18):7154-9. PMC: 3645534. DOI: 10.1073/pnas.1222509110. View

12.

Thiery J, Acloque H, Huang R, Nieto M . Epithelial-mesenchymal transitions in development and disease. Cell. 2009; 139(5):871-90. DOI: 10.1016/j.cell.2009.11.007. View

13.

Denzler R, Agarwal V, Stefano J, Bartel D, Stoffel M . Assessing the ceRNA hypothesis with quantitative measurements of miRNA and target abundance. Mol Cell. 2014; 54(5):766-76. PMC: 4267251. DOI: 10.1016/j.molcel.2014.03.045. View

14.

Aragona M, Panciera T, Manfrin A, Giulitti S, Michielin F, Elvassore N . A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell. 2013; 154(5):1047-1059. DOI: 10.1016/j.cell.2013.07.042. View

15.

Gradishar W, Anderson B, Balassanian R, Blair S, Burstein H, Cyr A . Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(3):324-54. DOI: 10.6004/jnccn.2016.0037. View

16.

Kim J, Jo H, Hong H, Kim M, Kim J, Lee J . Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking. Nat Commun. 2015; 6:6781. DOI: 10.1038/ncomms7781. View

17.

Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley T . Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell. 2017; 20(3):303-314.e5. PMC: 5337165. DOI: 10.1016/j.stem.2016.11.004. View

18.

Gupta P, Onder T, Jiang G, Tao K, Kuperwasser C, Weinberg R . Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659. PMC: 4892125. DOI: 10.1016/j.cell.2009.06.034. View

19.

Moroishi T, Hayashi T, Pan W, Fujita Y, Holt M, Qin J . The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. Cell. 2016; 167(6):1525-1539.e17. PMC: 5512418. DOI: 10.1016/j.cell.2016.11.005. View

20.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View